Neuspera Medical, a San Jose, CA-based neuromodulation company, raised $23M in Series D funding.
The round was led by Vertex Ventures HC and Treo Ventures with participation from Action Potential Venture Capital, Windham Venture Partners, Olympus Innovation Ventures and another strategic investor.
The company intends to use the funds to further enhance its growth through expected U.S. Food and Drug Association (FDA) premarket approval (PMA) of its system.
Led by CEO Steffen Hovard, Neuspera Medical is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses. The company is advancing a discreet, minimally invasive, ultra-miniaturized implant designed to provide patients personal control and relief from urinary urge incontinence (UUI), a symptom of overactive bladder (OAB).
The Neuspera System includes an ultra-miniaturized pulse generator attached to an electrode array.
FinSMEs
15/07/2024